VEGFA and hepatocellular carcinoma: In contrast, tyrosine kinase inhibitor/anti-VEGF therapies have similar treatment efficacy with HRs for OS at 0.81 (95% CI, 0.71–0.92) for HCC of viral etiology and 0.82 (95% CI,0.67–1.01) for that of nonviral etiology (p = 0.8828) (Haber et al., 2021).